LY 2584702

Drug Profile

LY 2584702

Alternative Names: LY-S6K1; LY2584702; LYS 6K1 tosylate; P70 inhibitor

Latest Information Update: 07 Feb 2012

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics
  • Mechanism of Action 70 kDa ribosomal protein S6 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 10 Jan 2012 Discontinued - Phase-I for Solid tumours in Japan (PO)
  • 10 Jan 2012 Discontinued - Phase-I for Solid tumours in Singapore (PO)
  • 10 Jan 2012 Discontinued - Phase-I for Solid tumours in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top